All In Biotech

Drug Trial Radar · NCT07332481

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-1)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

202

Planned (sponsor's estimate)

Start

Mar 10, 2026

Primary completion

May 24, 2029

Study completion May 24, 2029

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jan 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Cutaneous Lupus Erythematosus (CLE)

Interventions

  • EnpatoranDrug

    Participants will receive a dose of Enpatoran orally twice daily from Day 1 to Day 168.

  • PlaceboDrug

    Participants will receive a single oral dose of a placebo matching Enpatoran tablet twice daily from Day 1 to Day 168.

  • Standard of care (SoC)Drug

    Participants will receive Investigator-recommended SoC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 Response, Defined as >= 70 Percent (%) Decrease in CLASI-A Score From BaselineTime frame: At Week 24

Locations

74 sites in 20 countries. Site status is shown where the registry gives one.

  • Dermatology Research Associates - 300204025

    Los Angeles, California · Recruiting

  • Cohen Medical Centers

    Thousand Oaks, California · Recruiting

  • GNP Research at Mark Jaffe, MD

    Cooper City, Florida · Recruiting

  • Advance Medical Research Center

    Miami, Florida · Recruiting

  • Diverse Clinical Research LLC

    Miami, Florida · Recruiting

  • D&H National Research Centers, Inc.

    Tamarac, Florida · Recruiting

  • Clinical Research of West Florida, Inc.

    Tampa, Florida · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • Revival Research Institute, LLC

    Troy, Michigan · Recruiting

  • Allen Arthritis

    Allen, Texas · Recruiting

  • Arthritis and Rheumatology Research Institute PLLC

    Allen, Texas · Recruiting

  • Arthritis Care of Texas

    Corpus Christi, Texas · Recruiting

  • John Hunter Hospital - PARENT

    New Lambton Heights, New South Wales, Australia · Recruiting

  • Rheumatology Research Unit Sunshine Coast

    Maroochydore, Queensland, Australia · Recruiting

  • The Alfred Hospital - PARENT

    Melbourne, Victoria, Australia · Recruiting

  • UZ Leuven - Internal Medicine

    Leuven, Belgium · Recruiting

  • HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará

    Fortaleza, Ceará, Brazil · Recruiting

  • Clínica SER da Bahia

    Salvador, Estado de Bahia, Brazil · Recruiting

  • IPC MT Instituto de Pesquisas Clinicas do Mato Grosso

    Cuiabá, Mato Grosso, Brazil · Recruiting

  • Freire Pesquisa Clinica

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Hospital de Câncer de Barretos - Fundação Pio XII - Hospital de Amor de Barretos

    Barretos, São Paulo, Brazil · Recruiting

  • DCC V Plovdiv Sv. Archbishop Luka EOOD

    Plovdiv, Bulgaria · Recruiting

  • Ambulatory for Specialized Medical Help - skin and venereal diseases

    Sofia, Bulgaria · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Ganzhou People's Hospital - 300165192

    Ganzhou, Jiangxi, China · Recruiting

  • Hopital Tenon - service dermatologie et centre d'allergie

    Paris, France · Recruiting

  • CHU Saint Etienne - Hôpital Nord - service de medecine interne

    Saint-Étienne-de-Montluc, Pays de la Loire Region, France · Recruiting

  • Charité - Campus Charité Mitte - Klinik fuer Dermatol., Venerol., Allergologie

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Carl Gustav Carus TU Dresden

    Dresden, Germany · Recruiting

  • Elbekliniken Buxtehude GmbH - Dermatologie

    Buxtehude, Lower Saxony, Germany · Recruiting

  • Chaim Sheba Medical Center - pt

    Ramat Gan, Israel · Recruiting

  • Università Campus Bio-Medico di Roma - UOC Reumatologia

    Roma, Italy · Recruiting

  • Azienda USL Toscana Centro - Ospedale Piero Palagi

    Florence, Firenze, Italy · Recruiting

  • JCHO Chukyo Hospital - Dept of Dermatology

    Nagoya, Aichi-ken, Japan · Recruiting

  • NHO Chibahigashi National Hospital - Dept of Allergy/Rheumatology

    Chiba, Chiba, Japan · Recruiting

  • Hospital of the University of Occupational and Environmental Health - Dept of Dermatology

    Kitakyushu-shi, Fukuoka, Japan · Recruiting

  • Fukushima Medical University Hospital - Dept of Rheumatology/Immunology

    Fukushima, Fukushima, Japan · Recruiting

  • NHO Asahikawa Medical Center - Dept of Gastroenterology

    Asahikawa-shi, Hokkaido, Japan · Recruiting

  • Sapporo City General Hospital - Dept of Rheumatology/Immunology

    Sapporo, Hokkaido, Japan · Recruiting

  • Kobe University Hospital - Dept of Immunology/Rheumatology

    Kobe, Hyōgo, Japan · Recruiting

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.